COCHW · Insider Trading
Envoy Medical, Inc Warrant
Every open-market purchase and sale reported by COCHW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-04 | Brent T. Lucas | Chief Executive Officer | A | +32,856 | +$19.68K |
| 2026-04-17 | Chas McKhann | Director | A | +100,000 deriv. | — |
| 2026-02-17 | Mona Chetan Patel | Director | Buy | +312,500 | +$125.00K |
| 2026-02-17 | Charles Brynelsen | Director | Buy | +1,000,000 | +$400.00K |
| 2026-02-17 | Brent T. Lucas | Chief Executive Officer | Buy | +62,500 | +$25.00K |
| 2026-02-17 | Susan Kantor | Director | Buy | +96,150 | +$38.46K |
| 2026-02-17 | Robert Potashnick | Interim CFO | Buy | +212,500 | +$85.00K |
| 2026-02-17 | Glen A Taylor | 10%+ Owner | Buy | +18,750,000 | +$7.50M |
| 2026-02-09 | Robert Potashnick | Interim CFO | A | +15,000 deriv. | — |
| 2026-02-09 | Brent T. Lucas | Chief Executive Officer | A | — | — |
| 2025-12-10 | Brent T. Lucas | Chief Executive Officer | A | +18,105 | +$12.91K |
| 2025-12-05 | Janis Smith-Gomez | Director | A | +25,000 deriv. | — |
| 2025-12-05 | Mona Chetan Patel | Director | A | — | — |
| 2025-12-05 | Susan Kantor | Director | A | — | — |
| 2025-12-05 | Michael Curtis Crowe | Director | A | +25,000 deriv. | — |
| 2025-12-05 | Charles Brynelsen | Director | A | — | — |
| 2025-09-08 | Glen A Taylor | Director | MIXED | — | — |
| 2025-07-08 | Glen A Taylor | Director | A | — | — |
| 2025-06-13 | Mona Chetan Patel | Director | Buy | +2,500 | +$3.67K |
| 2025-06-10 | Mona Chetan Patel | Director | Buy | +10,000 | +$14.60K |
| 2025-06-09 | Brent T. Lucas | Chief Executive Officer | A | +12,907 | +$20.03K |
| 2025-05-27 | Charles Brynelsen | Director | Buy | +50,000 | +$82.40K |
| 2025-03-13 | Glen A Taylor | Director | A | — | — |
| 2024-12-26 | Susan Kantor | Director | J | +34,705 | — |
| 2024-12-26 | Anzu SPAC GP I LLC | 10%+ Owner | MIXED | −2,000,000 | — |
| 2024-12-17 | Glen A Taylor | Director | A | — | — |
| 2024-12-13 | Brent T. Lucas | Chief Executive Officer | Buy | — | — |
| 2024-11-22 | Mona Chetan Patel | Director | Buy | +2,500 | +$5.70K |
| 2024-11-21 | Whitney Haring-Smith | 10%+ Owner | J | −2,000,000 | — |
| 2024-11-21 | Susan Kantor | Director | J | +18,182 | — |
| 2024-09-11 | Mona Chetan Patel | Director | Buy | +5,000 | +$16.52K |
| 2024-08-29 | Glen A Taylor | Director | A | — | — |
| 2024-08-12 | Michael Curtis Crowe | Director | A | +25,000 deriv. | — |
| 2024-07-24 | Glen A Taylor | Director | A | — | — |
| 2024-06-26 | Brent T. Lucas | Chief Executive Officer | J | +84,960 | — |
| 2024-05-28 | Glen A Taylor | Director | A | — | — |
| 2024-03-04 | Glen A Taylor | Director | Buy | — | — |
| 2023-12-04 | Glen A Taylor | Director | J | — | — |
| 2023-11-24 | Brent T. Lucas | Chief Executive Officer | Buy | +12,380 | +$11.99K |
| 2023-11-22 | Glen A Taylor | Director | Buy | — | — |
| 2023-10-17 | Mona Chetan Patel | Director | A | +25,000 deriv. | — |
| 2023-10-17 | Susan Kantor | Director | A | — | — |
| 2023-10-17 | David R. Wells | Chief Financial Officer | A | +293,250 deriv. | — |
| 2023-10-17 | Janis Smith-Gomez | Director | A | +25,000 deriv. | — |
| 2023-10-17 | Charles Brynelsen | Director | A | +62,500 deriv. | — |
| 2023-10-17 | Brent T. Lucas | Chief Executive Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Glen A Taylor | Director | 26,513,991 | $665.50K |
| Anzu SPAC GP I LLC | 10%+ Owner | 2,028,986 | $50.93K |
| Charles Brynelsen | Director | 1,050,000 | $26.36K |
| Whitney Haring-Smith | 10%+ Owner | 1,000,000 | $25.10K |
| Brent T. Lucas | Chief Executive Officer | 342,666 | $8.60K |
| Mona Chetan Patel | Director | 332,500 | $8.35K |
| Robert Potashnick | Interim CFO | 212,500 | $5.33K |
| Susan Kantor | Director | 174,037 | $4.37K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the COCHW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.